Scarica l'app Stockscreener
103.50
0.17%
0.18
Dopo l'orario di chiusura:
103.73
0.23
+0.22%
Precedente Chiudi:
$103.32
Aprire:
$103.35
Volume 24 ore:
2.06M
Relative Volume:
0.68
Capitalizzazione di mercato:
$19.76B
Reddito:
$3.08B
Utile/perdita netta:
$-986.58M
Rapporto P/E:
-19.47
EPS:
-5.3172
Flusso di cassa netto:
$292.08M
1 W Prestazione:
+0.12%
1M Prestazione:
+0.31%
6M Prestazione:
+92.34%
1 anno Prestazione:
+121.91%
Intervallo 1D:
$103.26
$103.52
Intervallo di 1 settimana:
$103.10
$103.55
Portata 52W:
$38.81
$103.67
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
103.50 | 19.72B | 3.08B | -986.58M | 292.08M | -5.3172 |
|
TMO
Thermo Fisher Scientific Inc
|
501.97 | 194.93B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
195.50 | 142.84B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
608.41 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
115.07 | 33.38B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
302.54 | 30.96B | 3.17B | 642.63M | 516.49M | 10.77 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
CSLLY or EXAS: Which Is the Better Value Stock Right Now? - Yahoo! Finance Canada
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year - BioSpace
EXACT SCIENCES CORP (NASDAQ:EXAS) Shows Strong Technical and Fundamental Momentum - ChartMill
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration - BioSpace
Exact Sciences Stock: Is The Post-Earnings Slide A Buying Setup for 2026? - AD HOC NEWS
Exact Sciences (NASDAQ: EXAS) EVP exercises 3,900 options, 1,913 shares withheld - Stock Titan
Exact Sciences (EXAS) CEO reports RSU vesting and tax-withheld share dispositions - Stock Titan
KeyCare, Inc. announced that it has received $27.4 million in funding from a group of investors - marketscreener.com
Is Exact Sciences (EXAS) Pricing Reflect Long Term Cancer Screening Growth Potential - Yahoo Finance
Exact Sciences Corporation $EXAS Shares Sold by Fox Run Management L.L.C. - MarketBeat
EXAS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pentwater Capital Management LP's Exact Sciences Corp(EXAS) Holding History - GuruFocus
[Form 4] EXACT SCIENCES CORP Insider Trading Activity - Stock Titan
EXACT Sciences (EXAS) HR EVP awarded 23,224 RSUs in new grant - Stock Titan
Exact Sciences (EXAS) grants SVP Herriott 20,321 restricted stock units - Stock Titan
EXACT Sciences (EXAS) CEO receives major RSU grant and tax-share withholding - Stock Titan
Exact Sciences (EXAS) awards 28,063 restricted stock units to EVP Baranick - Stock Titan
Exact Sciences (NASDAQ: EXAS) EVP receives 38,707 restricted stock units - Stock Titan
Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval - Yahoo Finance
December 18th Options Now Available For EXACT Sciences (EXAS) - Nasdaq
Market Outlook: Is Exact Sciences Corporation showing insider buyingJuly 2025 Selloffs & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Abbott Labs Increases Dividends for 54 Years, Acquires Exact Sciences - Intellectia AI
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time - The Motley Fool
Abbott offers $20B in notes to finance Exact Sciences acquisition - MassDevice
Abbott Laboratories (ABT) sells $20B of notes to finance Exact Sciences acquisition - Stock Titan
Exact Sciences stock hits 52-week high at $103.55 By Investing.com - Investing.com India
Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal - Bloomberg
Abbott lines up one of the year's biggest bond sales at $20B - Crain's Chicago Business
Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition - Quiver Quantitative
Exact Sciences Stockholders Approve Abbott Merger as Executive Pay Proposal Fails at Special Meeting - Yahoo Finance
Exact Sciences (NASDAQ:EXAS) Hits New 52-Week HighTime to Buy? - MarketBeat
Abbott kicks off bond sale for Exact Sciences deal - Modern Healthcare
Exact Sciences stock hits 52-week high at $103.55 - Investing.com
Abbott Laboratories Commences 8-Part Bond Sale Tied to Exact Sciences Acquisition, Bloomberg Reports - marketscreener.com
Exact Sciences shareholders approve merger with Abbott Laboratories By Investing.com - Investing.com Nigeria
Exact Sciences (EXAS) Shareholders Approve Abbott Acquisition - GuruFocus
Exact Sciences shareholders approve merger with Abbott Laboratories - Investing.com
Exact Sciences stockholders approve acquisition by Abbott - marketscreener.com
Exact Sciences shareholders approve Abbott acquisition - Investing.com
Exact Sciences Shareholders Approve Acquisition by Abbott Laboratories - marketscreener.com
Exact Sciences shareholders approve $105 per share Abbott acquisition - StreetInsider
Exact Sciences Stockholders Approve Acquisition by Abbott - The Chronicle-Journal
Exact Sciences Corp.: The Quiet Cancer-Test Stock Everyone’s Watching - AD HOC NEWS
Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up - The Globe and Mail
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock - Yahoo Finance
Aberdeen Group plc Increases Stock Position in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation $EXAS is Eagle Health Investments LP's 10th Largest Position - MarketBeat
Assessing Exact Sciences (EXAS) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
How The Abbott Offer Is Rewriting The Story For Exact Sciences (EXAS) - Yahoo Finance
How Investors May Respond To Exact Sciences (EXAS) Narrowing Losses And Oncotype DX Milestone - Yahoo Finance
Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports - MSN
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exact Sciences Corp Azioni (EXAS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Condella Sarah | EVP, Human Resources |
Feb 27 '26 |
Option Exercise |
5.03 |
3,900 |
19,617 |
133,034 |
| ORVILLE JACOB A | EVP, GM, Screening |
Dec 23 '25 |
Option Exercise |
0.00 |
73,080 |
0 |
69,511 |
| Baranick Brian | EVP, GM, Precision Oncology |
Dec 23 '25 |
Option Exercise |
0.00 |
73,080 |
0 |
66,487 |
| Condella Sarah | EVP, Human Resources |
Dec 23 '25 |
Option Exercise |
0.00 |
47,208 |
0 |
118,059 |
| Herriott James | SVP, General Counsel & Sec |
Dec 23 '25 |
Option Exercise |
0.00 |
33,780 |
0 |
32,934 |
| Bloomer Aaron | EVP, Chief Financial Officer |
Dec 23 '25 |
Option Exercise |
0.00 |
63,099 |
0 |
59,571 |
| ORVILLE JACOB A | EVP, GM, Screening |
Nov 19 '25 |
Sale |
75.00 |
5,000 |
375,000 |
23,237 |
| Herriott James | SVP, General Counsel & Sec |
Nov 19 '25 |
Sale |
70.00 |
1,000 |
70,000 |
11,585 |
2.34%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):